Xencor (NASDAQ:XNCR) Hits New 52-Week Low – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR) hit a new 52-week low during trading on Tuesday . The stock traded as low as $12.23 and last traded at $12.61, with a volume of 61223 shares. The stock had previously closed at $12.95.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on XNCR. Wells Fargo & Company reduced their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Trading Down 6.4 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market cap of $779.31 million, a price-to-earnings ratio of -3.46 and a beta of 0.74. The business’s fifty day moving average price is $15.89 and its 200 day moving average price is $20.21.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Xencor during the 4th quarter worth about $34,000. GAMMA Investing LLC raised its position in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares in the last quarter. Quarry LP lifted its stake in shares of Xencor by 111.4% in the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 2,108 shares during the period. Finally, KBC Group NV boosted its position in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.